Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Peritoneal Neoplasms

Peritoneal Neoplasms

Part of Cancer

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Peritoneal Neoplasms

16 trials tracked for Peritoneal Neoplasms: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 410 citations.

16Trials tracked
6Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 6 Phase 2 7 Phase 1 2 Other / NA 1
  1. Phase 3 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed · 410 cited
  2. Phase 3 Adjuvant HIPEC in High Risk Colon Cancer Completed · 322 cited
  3. Phase 3 A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed · 43 cited
  4. Phase 3 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Completed
  5. Phase 3 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Completed
  6. Phase 3 LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer Completed
Show 10 more trials
  1. Phase 2 Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis Completed
  2. Phase 2 Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT Completed
  3. Phase 2 Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis Completed
  4. Phase 2 A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers Completed
  5. Phase 2 Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer Completed
  6. Phase 2 Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma Completed
  7. Phase 2 Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy Completed
  8. Phase 1 Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. Completed
  9. Phase 1 BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer Completed
  10. N/A Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy Completed

Showing the 16 most-cited and recently-updated of 16 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Peritoneal Neoplasms: what the trials found

New evidence indicates that Paclitaxel is associated with a 75.0% probability of peritoneal progression-free survival (pPFS) in specific cohorts, though no participants achieved a clinicopathologic response or became resectable under this regimen 1. In larger Phase 3 trials, Paclitaxel demonstrated median progression-free survival (PFS) of 18.37 to 19.48 months in the intent-to-treat population; notably, a statistically significant improvement in PFS was observed in the PD-L1-positive subpopulation (20.83 vs. 18.50 months, p=0.0376) 2.

Immunotherapy with Pembrolizumab showed a statistically significant improvement in progression-free survival (PFS) for all participants (22.2 vs. 15.2; 14.6_p<0.0001) and specifically in patients with PD-L1 positive tumors (CPS ≥ 10) (23.9 vs. 17.3; 15.2, p=0.0002). While Pembrolizumab improved PFS, it did not result in a statistically significant difference in overall survival (OS) for the PD-L1 positive cohort 5.

Other systemic treatments include Trabectedin, which showed a significantly higher objective response rate (ORR) of 46.0% compared to 35.9% (p=0.0142), though it did not reach statistical significance in terms of overall survival or progression-free survival 4. Standard adjuvant systemic chemotherapy was associated with a peritoneal recurrence-free survival at 18 months of approximately 79-80% 3. Gemcitabine showed no statistically significant difference in PFS, response rate, or time to treatment failure compared to control groups 7.

In studies comparing active treatments against placebo, the intervention group demonstrated a statistically significant improvement in progression-free survival (PFS) based on mRECIST and additional clinical criteria 6.

Recent results — preliminary, needs further review

  • Topotecan was evaluated in a Phase 2 trial but results are not yet corroborated 8.
  • IPCI (CDDP+5FU) showed a significantly higher objective response rate (77.7% vs. 63.8%, p=0.0140) and lower adverse event rates compared to the control group, while also showing significant differences in quality of life scores 9.
  • Farletuzumab was associated with a 25.6% rate of participants experiencing prolonged remission 12.

For the clinician treating this condition

  • Pembrolizumab significantly improves progression-free survival (PFS) in patients with peritoneal neoplasms, particularly those with PD-L1 positive tumors (CPS ≥ 10).
  • Paclitaxel shows a statistically significant PFS benefit specifically within the PD-L1-positive subpopulation.
  • Trabectedin provides a significantly higher objective response rate compared to its respective control group, despite non-significant improvements in OS and PFS.

AI synthesis of 10 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.

Research across Cancer

Related studies from across the Cancer family.

Review of a case report on epithelioid clear cell mesothelioma in a 76-year-old male with 24 months follow-up
Oncology Sys. Review
Review of a case report on epithelioid clear cell mesothelioma in a 76-year-old male with 24 months follow-up A 76-year-old man with rare cancer stayed cancer-free for two years
This publication is a review of a single case report involving a 76-year-old male with epithelioid clear cell mesothelioma. The patient had …
A 76-year-old man with a rare form of cancer had no signs of the disease returning after two years, offering hope for others facing this dif…
Frontiers May 18, 2026
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients
Oncology RCT
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients Chemo before surgery may reduce tumor burden in colorectal cancer patients
This phase II randomized controlled trial evaluated 53 patients with resectable peritoneal metastasis of colorectal cancer.
A trial suggests chemo before surgery might lower tumor markers for colorectal cancer patients with spread to the abdomen.
Apr 28, 2026
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
Oncology RCT
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone New Drug Combo Extends Survival for Tough Ovarian Cancer
This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participant…
This new combination offers a meaningful survival boost for women with recurrent ovarian cancer that has become resistant to standard treatm…
Apr 23, 2026